The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney diseaseKen Ohara, Daisuke Nagata, Tetsu Akimoto et al.|Diabetology & Metabolic Syndrome|2020Cited by 66
Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY TrialKentaro Oka, Daisuke Nagata, Takahiro Masuda et al.|Frontiers in Medicine|2023Cited by 16
Sodium–Glucose Cotransporter 2 Inhibitor Combined with Conventional Diuretics Ameliorate Body Fluid Retention without Excessive Plasma Volume ReductionMaki Asakura-Kinoshita, Daisuke Nagata, Takahiro Masuda et al.|Diagnostics|2024Cited by 14
Tubulointerstitial nephritis in antineutrophil cytoplasmic antibody-associated vasculitis with monoclonal gammopathyErika Hishida, Daisuke Nagata, Takahisa Kobayashi et al.|CEN Case Reports|2021Cited by 5
SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trialTakahiro Masuda, Yoshiyuki Morishita, Maki Asakura-Kinoshita et al.|Hypertension Research|2025Cited by 5